Please assess the completion status of the following clinical trial:

Trial Title: PaTH Study: Parathyroid Hormone and Alendronate for Osteoporosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Aged between 55 and 85 years~* Postmenopausal (have not had any menses in the last 5 years)~* Have a bone mineral density scan (DXA) that can be evaluated at the spine AND at the hip with a T-score equal to or below -2.5 at the spine or the femoral neck or total hip OR T-score equal to or below -2.0 at the spine or the femoral neck or total hip and have at least one of the following risk factors for fracture: (a) age \> 65 years; (b) history of postmenopausal fracture (nonvertebral or vertebral); or (c) maternal history of hip fracture~* Willing and able to self-administer daily injections~Exclusion Criteria:~* Have used estrogen (oral or patch) for more than 1 month in the last 6 months or more than 12 months in the last 2 years~* History of more than 12 months of bisphosphonate use ever, or any use (\> 4 weeks) within the past 12 months~* History of rhPTH (recombinant human PTH) use~* Any major life-threatening illnesses~* Type 1 or uncontrolled type 2 diabetes mellitus (defined as hemoglobin A1C \> 10.0), or currently using insulin~* Vitamin D level \< 15 nanograms/ml~* History of kidney disease (creatinine \> 2.0 mg/dl)~* Renal insufficiency (creatinine clearance \< 40 mg/min)~* Any history of kidney stones~* Any history of hypercalciuria or currently have urine calcium/creatinine \>300 mg~* History of hypercalcemia, sarcoidosis, or hyperparathyroidism~* History of active or treated tuberculosis or other granulomatous disorders~* History of breast cancer, melanoma, or hematologic malignancy that has required treatment within the last 10 years~* History of bone cancer or any other metabolic bone disease that has required treatment within the last 10 years~* History of any other nonskin cancer that has required treatment within the last 10 years~* History of symptomatic esophageal reflux, achalasia or esophageal stricture~* Currently taking \> 7.5 mg systemic prednisone or equivalent per day~* Currently using \> two puffs, four times/day of inhaled steroids~* Currently taking anticoagulants or anticonvulsants~* Have used Calcitonin within the past 3 months~* Have used Raloxifene in the last 6 months or for more than 12 months in the last 2 years~* Have used Tamoxifen in the last 6 months or for more than 12 months in the last 2 years~* Have used fluoride for at least a month within the past 5 years~* Currently taking \> 1000 IU/day vitamin D or vitamin D analogues or metabolites~* Currently taking thyroid hormone replacement AND have a TSH \< 0.1mIU/L

- Gender: FEMALE
- Minimum Age: 55 Years
- Maximum Age: 85 Years
- Healthy Volunteers: t

Study Arms:
- 1 (Type: EXPERIMENTAL): Participants will receive PTH for 1 year followed by alendronate for 1 year.
- 2 (Type: EXPERIMENTAL): Participants will receive PTH and alendronate for 1 year followed by alendronate for 1 year.
- 3 (Type: EXPERIMENTAL): Participants will receive alendronate for 2 years.
- 4 (Type: ACTIVE_COMPARATOR): Participants will receive PTH for 1 year followed by placebo for 1 year.

Based on this trial design, predict the completion outcome and termination type (if applicable).